Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 1.00 |
| ▸ | NOS2 | P35228 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28377173 | 0.98 | NOS3 (0.95) | NOS3NOS2MAPK1NOS1LCK | |
| SCHEMBL20028512 | 0.81 | NOS3 (0.68) | NOS3NOS2MAPK1NOS1LCK | |
| SCHEMBL6299860 | 0.78 | NOS3 (0.64) | NOS3NOS2MAPK1NOS1LCK | |
| SCHEMBL18469859 | 0.78 | NOS3 (0.64) | NOS3NOS2MAPK1NOS1LCK | |
| SCHEMBL20003587 | 0.78 | NOS3 (0.64) | NOS3NOS2MAPK1NOS1LCK | |
| SCHEMBL23860983 | 0.76 | NOS3 (0.61) | NOS3NOS2MAPK1ALOX15ALDH1A1 | |
| SCHEMBL10265668 | 0.76 | NOS3 (0.61) | NOS3NOS2MAPK1LCKALOX15 | |
| SCHEMBL6264496 | 0.76 | NOS3 (0.61) | NOS3NOS2MAPK1NOS1LCK | |
| SCHEMBL8893556 | 0.76 | NOS3 (0.61) | NOS3NOS2ALOX15ALDH1A1SMN1; SMN2 | |
| SCHEMBL30133408 | 0.76 | NOS3 (0.61) | NOS3NOS2MAPK1ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8198851-A | — | — | None | — | — | JP | disclosed |
| JP-60112768-A | — | — | None | — | — | JP | disclosed |
| WO-2023072273-A1 | POLYCYCLIC COMPOUND AS CBL-B INHIBITOR | 先声再明医药有限公司 | 2023-05-04 | — | — | WO | disclosed |
| CN-107922406-B | CGRP receptor antagonists | 伊兰科美国公司 | 2020-04-03 | — | — | CN | disclosed |
| WO-2020035065-A1 | PYRAZOLE DERIVATIVE AS RET INHIBITOR | 南京明德新药研发有限公司 | 2020-02-20 | — | — | WO | disclosed |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-21 | — | — | US | disclosed |
| EP-3152193-B1 | TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE INHIBITION OF THE HSP70 PROTEIN | HOLZGRABE ULRIKE (DE) | 2018-03-28 | — | — | EP | disclosed |
| US-20170152229-A1 | TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE INHIBITION OF THE HSP70 PROTEIN | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2017-06-01 | — | — | US | disclosed |
| EP-3004107-B1 | 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-10 | — | — | EP | disclosed |
| US-20170097567-A1 | METHOD FOR PRODUCING POLYMER | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-04-06 | — | — | US | disclosed |
| EP-1899322-B1 | ISOQUINOLINE DERIVATIVES AS INHIBITORS OF RHO-KINASE | SANOFI AVENTIS (FR) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008145963-A1 | 2-OXO-2- (2-PHENYL-5,6,7,8-TETRAHYDRO-INDOLIZIN-3-YL) -ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ANTIFUNGAL AGENTS | F2G LIMITED (GB) | 2008-12-04 | — | — | WO | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| US-7329660-B2 | Phthalazine derivatives for treating inflammatory diseases | NOVARTIS AG (CH) | 2008-02-12 | — | — | US | disclosed |
| EP-1219609-B1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO (JP) | 2007-04-04 | — | — | EP | disclosed |
| JP-H08198851-A | SYNTHESIS OF METHYLAMINOPYRIDINE DERIVATIVE | NISSHIN FLOUR MILLING CO LTD | 1996-08-06 | — | — | JP | disclosed |
| US-5290797-A | Benzopyran compounds | ADIR ET COMPAGNIE (FR) | 1994-03-01 | — | — | US | disclosed |
| US-4869983-A | SENSITIZERS, CHARGE GENERATING COMPOUNDS | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-09-26 | — | — | US | disclosed |
| JP-S60112768-A | METHYLAMINOPYRIDINE DERIVATIVE | TOYO SODA MFG CO LTD | 1985-06-19 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152229-A1 | TETRAHYDROISOQUINOLINONE DERIVATIVES AND THEIR USE IN THE INHIBITION OF THE HSP70 PROTEIN | HSPH1, HSP90AB1, HSP90AB2P | NOS3 2652/4885NOS2 1617/4885MAPK1 2200/4885 |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | NOS3 1823/4885NOS2 2195/4885MAPK1 2347/4885 |
| US-20190055257-A1 | SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | GRM2, GRM5, GRM1 | NOS3 3652/4885NOS2 2712/4885MAPK1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.